 |
|
|
|
|
|
 |
Diseases |
|
|
| Title |
 |
Publication Date |
 |
Price |
|
|
|
|
World Market for Pain Management Drugs and Devices
2nd Edition
|
December 2012 |
£1765 |
CNS Generic Drugs: Prospects and Opportunities to 2012
|
April 2008 |
£995 |
Stakeholder Opinions: Percutaneous Coronary Intervention
Adverse events with drug-eluting stents demand a new safety standard
|
April 2008 |
£2000 |
Commercial and Pipeline Insight: HRT for Menopausal Symptoms
A new class restores an old market
|
April 2008 |
£8000 |
Commercial Insight: CNS Market Overview
Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors
|
April 2008 |
£8000 |
Stakeholder Opinions: Heart Failure
When drugs do not work
|
April 2008 |
£2000 |
Commercial and Pipeline Insight: ADHD
Immature adult market continues to offer greatest commercial potential
|
April 2008 |
£8000 |
MarketWatch: Cancer
|
April 2008 |
£110 |
MarketWatch: CNS
|
April 2008 |
£110 |
Companion Diagnostics in Personalized Medicine and Cancer Therapy
|
April 2008 |
£1715 |
Cancer Diagnostic Testing World Markets
|
April 2008 |
£1715 |
Stakeholder Opinions: Sepsis
The Critical Care Community Gains Critical Mass
|
March 2008 |
£2000 |
Pipeline and Commercial Insight: Alzheimer's Disease
Scenario Forecasts Reveal Vast Market Potential
|
March 2008 |
£7600 |
Stakeholder Opinions: Biologics in Infectious Diseases
Well Defined Target Populations Are Key to Commercial Success
|
March 2008 |
£2000 |
Stakeholder Opinions: Bone Metastases
Impending Patent Expiries May Help Make or Break Newer Agents
|
March 2008 |
£2000 |
Stakeholder Opinions: Systemic Lupus Erythematosus
Market Set to Enter Era of Biologic Therapies
|
March 2008 |
£2000 |
Alzheimer's Disease
New Drugs, Markets and Companies
|
March 2008 |
£1390 |
Pain Therapeutics
Drugs, Markets and Companies
|
March 2008 |
£1490 |
Cardiac Toxicity
|
March 2008 |
£1495 |
Cancer Cell Therapy Markets
|
March 2008 |
£1690 |
Drug Delivery in Cancer
Technologies, Markets and Companies
|
March 2008 |
£1490 |
Neuroprotection
Drugs, Markets and Companies
|
March 2008 |
£1740 |
The Cardiovascular Disorders Market Outlook to 2012
|
February 2008 |
£1995 |
The Cancer Market Outlook to 2012
|
January 2008 |
£1995 |
Peripheral Neuropathy and Neuropathic Pain, 2008
Current, Pipeline And Emerging Drugs For The Treatment Of Peripheral Neuropathy And Neuropathic Pain
|
January 2008 |
£1499 |
Parkinson's Disease Market analysis and forecasts
2008-2012, 2017 & 2022
|
January 2008 |
£1499 |
Cancer Stem Cells
Emerging Therapeutic, Diagnostic and Market Opportunities (2008)
|
January 2008 |
£1600 |
Urinary Incontinence - Lifecycle Management Strategies Retain Mid-Term Market Growth
Pipeline And Commercial Insight
|
December 2007 |
£7600 |
Acute Coronary Syndromes Fresh Look At Acs In Europe, What Is The Real Picture?
Stakeholder Insight
|
December 2007 |
£15200 |
Autoimmune Overview - Market Continues To Prosper
Commercial Insight
|
December 2007 |
£7600 |
Infectious Diseases Overview
Commercial Insight
|
December 2007 |
£7600 |
Diabetes
Stakeholder Insight
|
December 2007 |
£7600 |
Non-Hodgkin's Lymphoma - Is There Room To Emulate Rituxan's Success?
Stakeholder Opinions
|
December 2007 |
£2000 |
Substance Dependence - Part II: Alcohol
Pipeline Insight
|
December 2007 |
£3800 |
Peripheral Artery Disease Poor Disease Awareness Hinders New Agents
Pipeline Perspectives
|
December 2007 |
£3800 |
Orphan Diseases In CNS - Part II Amyotrophic Lateral Sclerosis
Pipeline Insight
|
December 2007 |
£3800 |
Hepatitis C - Small-Molecule Antivirals Pave The Way For Triple Therapy
Stakeholder Opinions
|
December 2007 |
£2000 |
Myelodysplastic Syndromes - First Approvals Spur Some Interest In A Niche Market
Stakeholder Opinions
|
December 2007 |
£2000 |
Inflammatory Bowel Disease - Debate Over Early Aggressive Treatment Continues
Stakeholder Insight
|
December 2007 |
£7600 |
Parkinson's Disease - Evidence Of Neuroprotection Essential To Progress Treatment Dynamics
Stakeholder Insight
|
December 2007 |
£7600 |
Multiple Myeloma - Exploring New Targets For Multiple Drug Therapy
Stakeholder Opinions
|
December 2007 |
£2000 |
Endometriosis - Scientific Clarity Will Unlock Market Potential Stakeholder Opinions
|
December 2007 |
£2000 |
HIV - Novel Nnrtis Address Crucial Unmet Need
Pipeline Insight
|
December 2007 |
£6000 |
Stakeholder Insight
Prostate Cancer - Hormone-refractory patients still waiting for treatment breakthroughs
|
December 2007 |
£7600 |
Parkinson's Disease in Focus
|
December 2007 |
£29.95 |
Stakeholder Opinions: Head and Neck Cancer
Innovatives to Change the Face of Treatment
|
November 2007 |
£2000 |
Who's Developing What in New Cancer Drugs 2006?
|
November 2007 |
£495 |
Commercial and Pipeline Insight: Systemic antifungals
|
November 2007 |
£7600 |
Pipeline Insight Migraine
Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries
|
November 2007 |
£2995 |
Pipeline Insight: Orphan Diseases in CNS - Part I: Huntington's Disease
|
November 2007 |
£3800 |
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
|
November 2007 |
£2495 |
Pipeline Insight Therapeutic Cancer Vaccines
A turbulent path from bench to bedside
|
October 2007 |
£2995 |
Stakeholder Insight Alzheimer's Disease
PharmaVitae Profile
|
October 2007 |
£2995 |
The Global Pain Therapeutics Market
Market Analysis, R&D Pipelines and Competitive Landscape
|
October 2007 |
£1515 |
Pipeline Insight: Molecular Targeted Cancer Therapies Can anything else revolutionize the market?
- Cancer
|
October 2007 |
£7600 |
The CNS Market Outlook To 2012
|
October 2007 |
£1495 |
Pipeline And Commercial Insight: Parkinson's Disease
Market To Grow As First Round Of Lifecycle Management Strategies Succeed
|
September 2007 |
£7600 |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£7600 |
Commercial Insight: Migraine
Opportunities Will Exist In The Wake Of Generic Attack
|
September 2007 |
£7600 |
Commercial Insight: Epilepsy
Companies Committed To The Cause Will Reap The Benefits
|
September 2007 |
£7600 |
Pipeline Insight: Neuropathic Pain
Emerging Drugs Fail To Capitalize In Lucrative Market
|
September 2007 |
£600 |
Cancer Vaccine Developments to 2011
|
September 2007 |
£1296 |
Innovations in Cardiovascular Disease Management
Latest surgical procedures, drugs and medical devices
|
September 2007 |
£1495 |
Decoding Big Pharmas R&D Strategy in Oncology
|
September 2007 |
£2495 |
Competitor Analysis: VEGF and VEGF-R Agonists, Antagonists and Inhibitors
|
August 2007 |
£198 |
VEGF and VEGF-R Agonists, Antagonists and Inhibitors
Competitor Analysis
|
August 2007 |
£198 |
Analytical Tool - Targeted Therapeutics: Melanoma
|
July 2007 |
£2105 |
Melanoma - Targeted Therapeutics
|
July 2007 |
£1325 |
Commercial Insight: HIV - Reshaping Treatment Paradigms
|
July 2007 |
£7600 |
Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential
Combination Products Still Have Blockbuster Potential
|
July 2007 |
£7600 |
Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
|
July 2007 |
£7600 |
Disease Management and Drug Adherence
Strategies to support patients and enhance treatment persistence
|
July 2007 |
£3800 |
Stakeholder Opinions: Primary Brain Cancer
Temozolomide Turns Heads
|
July 2007 |
£2000 |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
|
July 2007 |
£3510 |
The Global HIV/Aids Market Outlook To 2012
|
July 2007 |
£1495 |
Innovative And Targeted Cancer Therapies
Key Technologies, New Applications And Leading Players
|
July 2007 |
£1495 |
Blood Glucose Testing and Diabetes Management
|
July 2007 |
£1690 |
Commercial Insight: Depression
Atypical lifecycle management strategy rejuvenates depression market
|
June 2007 |
£7600 |
Commercial Insight: Osteoporosis
Risk management and reformulation offer best defense against generic onslaught
|
June 2007 |
£7600 |
Commercial Insight: Multiple Sclerosis Continued growth makes the MS market a highly attractive investment
|
June 2007 |
£7600 |
Stakeholder Opinions: Irritable Bowel Syndrome
Potentially profitable market is open for the taking
|
June 2007 |
£1900 |
Stakeholder Opinions: Irritable Bowel Syndrome
Potentially profitable market is open for the taking
|
June 2007 |
£1900 |
Stakeholder Opinions: Hepatocellular Carcinoma
Opportune indication for novel therapies
|
June 2007 |
£2000 |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
|
June 2007 |
£1999 |
Antibody Drug Target Atlas in Oncology
|
June 2007 |
£2330 |
New Cancer Drug Tracker: Ticilimumab
|
June 2007 |
£495 |
New Cancer Drug Tracker: Telcyta
|
June 2007 |
£495 |
New Cancer Drug Tracker: Tykerb
|
June 2007 |
£495 |
New Cancer Drug Tracker:Satraplatin
|
June 2007 |
£495 |
New Cancer Drug Tracker: Ixabepilone
|
June 2007 |
£495 |
New Cancer Drug Tracker: AP23573
|
June 2007 |
£495 |
China Anti-tumor Drugs Market Report
2007
|
June 2007 |
£150 |
Stakeholder Opinions: Female Sexual Dysfunction
Results from Datamonitor's 2005 physician survey
|
June 2007 |
£2000 |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
|
June 2007 |
£3510 |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
|
June 2007 |
£3510 |
CNS Market Trends, 2007 to 2010
Key Market Forecasts and Growth Opportunities
|
June 2007 |
£995 |
New Cancer Drug Tracker: Vectibix
|
May 2007 |
£495 |
Lung Cancer Drug Pipeline Update 2006
|
May 2007 |
£1015 |
Pancreatic Cancer Drug Pipeline Update 2007
|
May 2007 |
£1015 |
Renal Cancer Drug Pipeline Update 2007
|
May 2007 |
£1015 |
CRC Drug Pipeline Update 2005
|
May 2007 |
£1015 |
Melanoma Drug Pipeline Update 2007
|
May 2007 |
£1015 |
Bladder Cancer Drug Pipeline Update 2007
|
May 2007 |
£680 |
Liver Cancer Drug Pipeline Update 2007
|
May 2007 |
£680 |
Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2006
Drug Pipeline Update 2007
|
May 2007 |
£1015 |
Ovarian Cancer Drug Pipeline Update 2007
|
May 2007 |
£1015 |
Analytical Tool: Prostate Cancer
A Therapeutic & Competitive Insight
|
May 2007 |
£2105 |
Analytical Tool: Apoptosis
Promise or deception?
|
May 2007 |
£2105 |
Analytical Tool – Hematological Cancers
|
May 2007 |
£4040 |
Hematological Cancers Drug Pipeline Update 2006
|
May 2007 |
£1355 |
Analytical Tool: Competitive Outlook on Cancer Vaccines
|
May 2007 |
£2105 |
Analytical Tool: Lymphoma Therapeutics & Competitive Insights
|
May 2007 |
£2105 |
Non-Antibody Based Cancer Vaccines: Drug Pipeline Update 2006
Drug Pipeline Update 2007
|
May 2007 |
£1015 |
Breast Cancer Drug Pipeline Update 2006
|
May 2007 |
£1015 |
Leukemia Drug Pipeline Update 2006
|
May 2007 |
£1015 |
Immunotherapy in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1355 |
Analytical Tool - Leukemia Therapeutics & Competitive Insights
|
May 2007 |
£2105 |
Analytical Tool - Competitive Outlook on Anti-Angiogenesis and Vascular Targeting in Oncology
|
May 2007 |
£2105 |
Analytical Tool: Analysis of Cancer Immunotherapy
The World Guide
|
May 2007 |
£3360 |
Analytical Tool: Breast Cancer R&D Comprehensive Guide
|
May 2007 |
£2105 |
Vascular Targeting and Anti-angiogenesis in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1015 |
Lymphoma Drug Pipeline Update 2006
|
May 2007 |
£1015 |
Antibodies in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1015 |
Analytical Tool: Current & Future Lung Cancer Therapeutics
|
May 2007 |
£2105 |
Prostate Cancer - A Therapeutic & Competitive Insight
Drug Pipeline Update 2007
|
May 2007 |
£1015 |
Apoptosis in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1015 |
Brain Cancer Drug Pipeline Update 2007
|
May 2007 |
£1525 |
Global Cancer Focus Company Directory
|
April 2007 |
£1325 |
Targeted Therapeutics in Non-Small Cell Lung Cancer
|
April 2007 |
£1325 |
Non-Small Cell Lung Cancer Drug Pipeline Update 2007
|
April 2007 |
£1015 |
Global Pipeline Review & Analysis of Hematological Malignancies
|
March 2007 |
£1665 |
Stakeholder Opinions: Asthma Phenotypes A changing paradigm
|
March 2007 |
£2000 |
GSK's Cervarix
A Future Blockbuster of 2007
|
March 2007 |
£1999 |
Stakeholder Opinions: Nosocomial Infections
The need for new gram-negative drugs
|
March 2007 |
£2000 |
Pipeline Insight: Depression
Novel drugs to grow third-line market
|
March 2007 |
£6000 |
Stakeholder Opinion: Atopic Dermatitis
A high level of unmet need creates market opportunities
|
March 2007 |
£2000 |
AMD Market Outlook to 2012
|
March 2007 |
£1299 |
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma
Limited R&D activity provides opportunity for early-phase pipeline drugs
|
March 2007 |
£2000 |
Stakeholder Opinions
Esophageal Cancer Treatment paradigms need revolution not evolution
|
March 2007 |
£2000 |
Immunotherapy of Cancer
|
March 2007 |
£2410 |
Diabetes & Obesity
A Competitor Analysis
|
March 2007 |
£675 |
Prostate and Breast Cancer- New Treatments & Developmental Progress
|
March 2007 |
£2000 |
Breast Cancer
The Latest R&D Trends
|
February 2007 |
£1325 |
New Cancer Drug Tracker: Acapodene
|
February 2007 |
£495 |
The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012
|
February 2007 |
£1499 |
Drug Treatments for Leading Endocrine and Metabolic Diseases
|
February 2007 |
£2410 |
Innovations in Cancer
Novel Therapeutics, New Diagnostics and Future R&D Strategies
|
February 2007 |
£1495 |
Diabetes Drug Discoveries
What the Future Holds
|
January 2007 |
£1495 |
Stakeholder Opinions Respiratory Syncytial Virus (RSV)
A market yet to reach its full potential
|
January 2007 |
£2000 |
World market for cancer vaccines 2007-2012
|
January 2007 |
£1999 |
Cardiac Marker Diagnostic Testing Markets
|
January 2007 |
£1690 |
Innovations in CNS
Novel therapeutics and future R&D strategies
|
January 2007 |
£1495 |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£4715 |
The Cardiovascular Market Outlook to 2011
|
January 2007 |
£1495 |
PPAR Agonists
Competitor Analysis
|
January 2007 |
£132 |
Competitor Analysis: PPAR Agonists
|
January 2007 |
£132 |
Commercial Insight: HIV
Change of guard
|
December 2006 |
£8000 |
Stakeholder Opinions: Respiratory Syncytial Virus (RSV)
A market yet to reach its full potential
|
December 2006 |
£2000 |
Stakeholder Insight: Multiple Sclerosis
Disease-modifying efficacy and side effects guide treatment choice
|
December 2006 |
£8000 |
Stakeholder Opinions: Melanoma
Lucrative commercial opportunities persist
|
December 2006 |
£2000 |
Stakeholder Opinion: Erectile Dysfunction
Identifying product differentiation and patient segmentation strategies
|
December 2006 |
£2000 |
Commercial and Pipeline Insight: Psoriasis
Anti-TNF's lead another indication
|
December 2006 |
£8000 |
Commercial Insight: Osteoarthritis
Market sees steady growth
|
December 2006 |
£8000 |
Stakeholder Insight: Atherosclerosis
HDL, ApoA-I, Carotid MRI and 64-slice CT offer opportunities for future treatment
|
December 2006 |
£8000 |
Commercial and Pipeline Perspectives: Obesity
Lack of Reimbursement Limits Market Potential
|
December 2006 |
£6000 |
Stakeholder Insight: Alzheimer's Disease
Prescribing trends indicate that neurologists are not adhering to guidelines
|
December 2006 |
£8000 |
Pipeline Insight: Therapeutic Cancer Vaccines
A turbulent path from bench to bedside
|
December 2006 |
£6000 |
Commercial Insight: Antibacterials
Growth in resistance rates drives niche indications
|
December 2006 |
£8000 |
Pipeline Insight: Migraine
Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries
|
December 2006 |
£6000 |
Competitive Outlook on Apoptosis in Oncology
|
December 2006 |
£1325 |
Stakeholder Insight: Pricing and Reimbursement in Oncology
Do payers believe oncology drugs offer good value?
|
December 2006 |
£6000 |
Stakeholder Opinions: Gynecological Cancers
Niche opportunities in advanced disease
|
December 2006 |
£2000 |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£3360 |
Preclinical Cancer Therapeutics 2007
Decoding Next Generation Drug Targets for Market Success
|
December 2006 |
£1600 |
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
|
December 2006 |
£3510 |
Cancer Market Trends 2006 - 2010
Key market forecasts and growth opportunities
|
December 2006 |
£1050 |
New Cancer Drug Tracker: Vatalanib
|
November 2006 |
£495 |
CNS Drug Discoveries: Sleep Disorders
|
November 2006 |
£795 |
CNS Drug Discoveries: Neurodegenerative Disorders
|
November 2006 |
£795 |
Commercial and Pipeline Insight: Inflammatory Bowel Disease
Competition Increases for the Biologics
|
November 2006 |
£6000 |
CNS Drug Discoveries: Depression
|
November 2006 |
£795 |
Stakeholder Insight: Respiratory Tract Infections in the USA
The demise of narrow-spectrum antibiotics
|
November 2006 |
£8000 |
CNS Drug Discoveries: Attention Deficit Hyperactivity Disorder (ADHD)
|
November 2006 |
£795 |
CNS Drug Discoveries: Multiple Sclerosis
|
November 2006 |
£795 |
Commercial and Pipeline Insight: Inflammatory Bowel Disease
Competition Increases for the Biologics
|
November 2006 |
£6000 |
Stakeholder Insight: Respiratory Tract Infections in the USA
The demise of narrow-spectrum antibiotics
|
November 2006 |
£8000 |
Pipeline Insight: Breakthrough Pain
Fast-acting players will capture majority market share
|
November 2006 |
£6000 |
Pipeline Insight: Osteoarthritis
The Wait for a DMOAD Continues
|
November 2006 |
£6000 |
Regulator Perceptions in Cancer
Evolving opinions about the oncology drug approval process
|
November 2006 |
£1000 |
Stakeholder Insight: Non-Small Cell Lung Cancer
The need for greater product differentiation in an increasingly crowded market
|
November 2006 |
£8000 |
Pipeline Insight: Asthma/COPD
Targeted therapies on the horizon
|
November 2006 |
£6000 |
CNS Market Outlook to 2011, The
|
November 2006 |
£1495 |
The CNS Market Outlook to 2011
|
November 2006 |
£1495 |
Pipeline Insight: Epilepsy
Pipeline drugs struggle to outshine their marketed predecessors
|
October 2006 |
£6000 |
Hematological Cancers - A Therapeutic & Competitive Insight
|
October 2006 |
£2000 |
Colorectal Cancer: Pipeline/Commercial Insight
Shaping the future dynamics of colorectal cancer management
|
October 2006 |
£8000 |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
|
October 2006 |
£8000 |
Stakeholder Insight: Atrial Fibrillation
Limited efficacy and poor safety lead to bleak outlook
|
October 2006 |
£8000 |
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
|
October 2006 |
£2340 |
Stakeholder Insight: Supportive Care in Cancer Treatment
Some first-generation products proving difficult to dislodge
|
October 2006 |
£8000 |
Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
|
October 2006 |
£1325 |
Leukemia - A Therapeutic & Competitive Insight
|
October 2006 |
£1325 |
The Cancer Market Outlook to 2011
|
October 2006 |
£1495 |
World Asthma and COPD Treatment Market, 2006-2011, The
A Changing Market with Increasing Potential
|
September 2006 |
£1499 |
Rheumatoid Arthritis: Market Trends and R&D Insights
|
September 2006 |
£620 |
Advanced Life Sciences' Cethromycin
Phase III success should allow 'me-too' market entry and above-consensus growth
|
September 2006 |
£2000 |
Pipeline Insight: Insulins
Inhalable insulins unlikely to become blockbusters
|
September 2006 |
£6000 |
Commercial Insight: Antihypertensives
New challenges for a maturing market
|
September 2006 |
£8000 |
Pipeline Insight: HIV
Extending treatment options
|
September 2006 |
£6000 |
Stakeholder Insight: Rheumatoid Arthritis
Biologics battle up the treatment algorithm
|
September 2006 |
£8695 |
Pipeline Insight: Bipolar Disorder
New treatments for bipolar depression set to drive near-term growth
|
September 2006 |
£6495 |
Competitor Analysis: Psoriasis
|
September 2006 |
£132 |
Psoriasis
Competitor Analysis
|
September 2006 |
£132 |
Emerging Opportunities in Cancer Nanomedicine
|
August 2006 |
£995 |
Commercial Insight: Antidiabetics
Patent expiries and cost containment initiatives balanced by pipeline products
|
August 2006 |
£8695 |
The Future of Metabolomics
Building competitive advantage in drug discovery, clinical development and diagnostics
|
August 2006 |
£1495 |
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome
Reformulations set to drive near-term growth
|
August 2006 |
£8695 |
Pipeline Insight: Non-insulin Antidiabetics
Type 2 diabetes unlikely to develop into a switch market
|
August 2006 |
£6495 |
Schizophrenia in Focus
|
August 2006 |
£29.95 |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£2340 |
Competitive Outlook on Non-Antibody Based Cancer Vaccines
|
August 2006 |
£1325 |
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
|
August 2006 |
£2340 |
Commercial Insight: Asthma/COPD
ICS/LABA combinations continue to dominate
|
August 2006 |
£8440 |
Global Diabetes Market; The
Therapeutics, Diagnostics and Complications
|
August 2006 |
£1240 |
Pipeline Insight: Schizophrenia
|
July 2006 |
£6330 |
Stakeholder Opinions: Parkinson's Disease
Review of Key Commercial Opportunities in the Symptomatic Treatment Market
|
July 2006 |
£2110 |
What's Hot in Cancer Drug R&D?
|
July 2006 |
£295 |
Stakeholder Opinions: Ovarian Cancer
Growing importance as secondary indication for targeted therapies
|
July 2006 |
£2195 |
Commercial Insight Top 20 Cancer Therapeutics
|
July 2006 |
£8695 |
Drug Targets for Breast Cancer
|
July 2006 |
£1095 |
Pain Therapeutics
New Times, New Targets
|
July 2006 |
£2750 |
Analytical Tool: The Commercial Success of Cancer Therapeutic Antibodies
|
June 2006 |
£2105 |
Pipeline Insight: Hepatitis C
Protease inhibitors to drive market expansion
|
June 2006 |
£6495 |
Management of Urinary Incontinence and Overactive Bladder
A Global Overview
|
June 2006 |
£8695 |
G-CSF and GM-CSF
Competitor Analysis
|
June 2006 |
£132 |
Insulin
Competitor Analysis
|
June 2006 |
£100 |
Competitor Analysis: EPO
|
June 2006 |
£132 |
